Study on the Mechanism of Action of Qiwei Huiyang Decoction Complex Preparation in the Treatment of Organ Injury after Hemorrhagic Shock

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400080673

Enrollment

Unknown

Registered

2024-02-04

Start date

2024-02-05

Completion date

Unknown

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Organ damage after hemorrhagic shock

Interventions

Experimental group:Patients with traumatic hemorrhagic shock who can take (oral or nasal) traditional Chinese medicine should be treated with Huiyang decoction.

Control group:The patients with traumatic hemorrhagic shock were treated conventionally without Qiwei Huiyang Decoction Complex Preparation.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old. 2. Meets the diagnosis of hemorrhagic shock, i.e. meets 2 of the following 123 criteria Item, or one of 456: 1) Changes in consciousness, such as restlessness, lack of consciousness, coma, etc; 2) Pulse rate,>100 beats/min or not palpable, shock index>1.0; 3) Skin is damp and cold, with positive finger pressure marks on the sternum (refilling time after finger pressure>2 seconds), visible freckles, pale mucosa or cyanosis on the skin, urine volume<30mL/h or no urine; 4) Systolic blood pressure<80mmHg; 5) Pulse pressure difference<20mmHg; 6) The systolic blood pressure of individuals with pre-existing hypertension decreases by more than 30% compared to the original systolic blood pressure. 3. At least one of CK, CK-MB, LDH, cTnI, BUN, and Scr were found to be abnormal upon admission.

Exclusion criteria

Exclusion criteria: 1: Multiple organ function deteriorates continuously within 24 hours of admission, and death occurs within 3 days. 2: Interventional surgery has been performed during the perioperative period. 3: Received CRRT treatment. 4: Chronic multiple organ dysfunction, immune disorders, hematological disorders, and tumors are present. 5: Application of tumor and immune related therapeutic drugs. 6: There are chronic intestinal diseases present.

Design outcomes

Primary

Measure	Time frame
Myocardial enzymes;Blood urea nitrogen (BUN) ;alanine aminotransferase (ALT) ;aspartate aminotransferase (AST);creatinine (Scr);	—

Secondary

Measure	Time frame
Hemoglobin;hematocrit;	—

Countries

China

Contacts

Public ContactXin Ge

Wuxi No.9 People’s Hospital affiliated to Soochow University

gexin2021@suda.edu.cn+86 158 5272 7979

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026